Tyers G F, Mills P, Clark J, Cheesman M, Yeung-Lai-Wah J A, Brownlee R R
Department of Surgery, University of British Columbia, Vancouver, Canada.
J Invest Surg. 1997 Jan-Apr;10(1-2):1-15. doi: 10.3109/08941939709032119.
The unacceptable rate of mechanical failures, threshold problems, and recalls experienced with many coaxial bipolar cardiac pacing lead designs are reviewed in detail. To address these problems, redundant insulation coradial atrial and ventricular tined leads (AL and VL, respectively) with iridium oxide electrodes were developed and subjected to extensive accelerated testing. There were no mechanical failures. The new lead body design proved to be much more durable than widely used trifilar MP35N configurations. The data reviewed and early and current test results are strongly supportive of tightly coupled insulation being a major factor in improving lead durability as long as the insulating material is not stressed. In addition to improving flex life, insulation adherence to the conductor may reduce the potential for ionic degradation. Pacing and sensing thresholds in animal studies of the new leads were within the reported range for leads with steroid eluting electrodes. A multicenter Canadian clinical trial was initiated with the first implant in early January 1994. By November 1995, 110 VL and 82 AL had been placed in 124 patients and followed for a mean of 11 +/- 6 months; maximum 21, total 1355. There were 60 males and 64 females with a mean age of 64 +/- 16 years, range 15-88. Primary indications for pacing were AV block in 61 patients, sick sinus syndrome in 53, vasovagal syncope in 4, and congestive heart failure in 7. Many patients had associated or primary tachyarrhythmias, including 111 with supraventricular and 12 with ventricular. Forty-two percent of patients (52/124) had prior cardiac procedures, including 18 open heart surgeries and 20 AV nodal ablations. At implant, 8 lead characteristics were rated good or excellent in 90% (746/829) of evaluations. X-ray visibility was of concern in 10% of patients (12/124). Three perioperative complications occurred, including displacement of one AL (1.2%) and one VL (0.9%). There were no subsequent mechanical (connector, conductor, or insulation) or functional (exit block, micro or macro displacement, or over- or undersensing) problems. Implant pacing thresholds (PT) at 0.45 ms were AL, 0.6 +/- 0.2 (74) and VL 0.4 +/- 0.2 V; impedance (Z) at 3.5 V output AL 373 +/- 77 (82) and VL 497 +/- 117 omega. Sensing thresholds (ST) were AL 3.1 +/- 1.6 (74) and VL 10.3 +/- 4.9 mV. Ventricular lead data were obtained for all patients (N = 110). Atrial lead data are incomplete, because some patients were in atrial fibrillation during implantation. After 12 months, AL PT at 1.5 V output was 0.18 +/- 0.10 ms (21) and at 2.5 V was 0.10 +/- 0.053 (22). Associated AL ST was 3.3 +/- 0.9 mV (21) AL Z 500 +/- 65 omega (25). After 18 months VL PT at 1.5 V was 0.15 +/- 0.10 ms (9) and at 2.5 V output was 0.09 +/- 0.04 ms (9). Associated VL ST was > 7.5 +/- 2.4 mV (9) and VL Z 497 +/- 105 omega (9). Follow-up time discrepancy is due to the VL being available 6 months earlier than the AL. There were no 30-day deaths and only one late death at 10 months in a patient with chronic atrial fibrillation. Death was unrelated to pacer or lead function. At 1 year, 68% AL (15/22) and 62% (24/39) captured at 0.5 V and < or = 1 ms pulse width output. Innovative adherent insulation coradial bipolar lead conductors of the design studied combined with coated iridium oxide electrodes provide for a negligible incidence of mechanical or functional failure with clinical follow-up now approaching 3 years. Excellent acute and chronic sensing and pacing thresholds have been documented. Late thresholds have continued to improve gradually. Long-term clinical pacing at < or = 1.5 V output with a large safety margin is feasible in essentially all patients. This coradial design produces very flexible < 5 French bipolar redundantly insulated lead bodies allowing both AL and VL to simultaneously pass through a single 10 French introducer sheath. (ABSTRACT TRUNCATED)
详细回顾了许多同轴双极心脏起搏导线设计中出现的机械故障、阈值问题和召回率过高的情况。为了解决这些问题,研发了带有氧化铱电极的冗余绝缘同心心房和心室翼状导线(分别为AL和VL),并进行了广泛的加速测试。未出现机械故障。新的导线体设计被证明比广泛使用的三线MP35N配置耐用得多。回顾的数据以及早期和当前的测试结果有力地支持了紧密耦合绝缘是提高导线耐用性的主要因素,只要绝缘材料不受应力影响。除了提高弯曲寿命外,绝缘层与导体的附着可能会降低离子降解的可能性。新导线在动物研究中的起搏和感知阈值在报道的带有类固醇洗脱电极的导线范围内。1994年1月初启动了一项加拿大多中心临床试验,首例植入。到1995年11月,已在124例患者中植入了110根VL和82根AL,并平均随访了11±6个月;最长21个月,总计1355个月。有60名男性和64名女性,平均年龄64±16岁,范围15 - 88岁。起搏的主要适应证为61例患者的房室传导阻滞、53例病态窦房结综合征、4例血管迷走性晕厥和7例充血性心力衰竭。许多患者伴有或原发性心律失常,包括111例室上性和12例室性。42%的患者(52/124)有过心脏手术史,包括18例心脏直视手术和20例房室结消融术。植入时,8项导线特征在90%(746/829)的评估中被评为良好或优秀。10%的患者(12/124)担心X线可见性。发生了3例围手术期并发症,包括1根AL移位(1.2%)和1根VL移位(0.9%)。随后未出现机械性(连接器、导体或绝缘)或功能性(出口阻滞、微或宏观移位、或感知过度或不足)问题。在0.45毫秒时的植入起搏阈值(PT),AL为0.6±0.2(74)V,VL为0.4±0.2 V;在3.5 V输出时的阻抗(Z),AL为373±77(82)Ω,VL为497±117Ω。感知阈值(ST),AL为3.1±1.6(74)mV,VL为10.3±4.9 mV。获取了所有患者(N = 110)的心室导线数据。心房导线数据不完整,因为一些患者在植入时处于房颤状态。12个月后,AL在1.5 V输出时的PT为0.18±0.10毫秒(21),在2.5 V时为0.10±0.053(22)。相关的AL ST为3.3±0.9 mV(21),AL Z为500±65Ω(25)。18个月后,VL在1.5 V时的PT为0.15±0.10毫秒(9),在2.5 V输出时为0.09±0.04毫秒(9)。相关的VL ST>7.5±2.4 mV(9),VL Z为497±105Ω(9)。随访时间差异是因为VL比AL早6个月可用。无30天死亡病例,仅1例在10个月时出现晚期死亡,该患者患有慢性房颤。死亡与起搏器或导线功能无关。1年时,68%的AL(15/22)和62%(24/39)在0.5 V和≤1毫秒脉冲宽度输出时捕获。所研究设计的创新型附着绝缘同心双极导线导体与涂覆氧化铱电极相结合,在临床随访接近3年时,机械或功能故障的发生率可忽略不计。已记录到出色的急性和慢性感知及起搏阈值。晚期阈值持续逐渐改善。基本上所有患者在输出≤1.5 V且有较大安全裕度的情况下进行长期临床起搏是可行的。这种同心设计产生了非常灵活的<5F双极冗余绝缘导线体,允许AL和VL同时通过单个10F导入鞘。(摘要截断)